Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 234

1.

Squamous Cell Carcinoma Following Photodynamic Therapy for Cutaneous Bowen's Disease in a Series of 105 Patients.

Ratour-Bigot C, Chemidling M, Montlahuc C, Abirached G, Madjlessi N, Bullier C, Battistella M, Bagot M, Lebbe C, Basset-Seguin N.

Acta Derm Venereol. 2015 Dec 30. doi: 10.2340/00015555-2330. [Epub ahead of print]

2.

PARKIN Inactivation Links Parkinson's Disease to Melanoma.

Hu HH, Kannengiesser C, Lesage S, André J, Mourah S, Michel L, Descamps V, Basset-Seguin N, Bagot M, Bensussan A, Lebbé C, Deschamps L, Saiag P, Leccia MT, Bressac-de-Paillerets B, Tsalamlal A, Kumar R, Klebe S, Grandchamp B, Andrieu-Abadie N, Thomas L, Brice A, Dumaz N, Soufir N.

J Natl Cancer Inst. 2015 Dec 17;108(3). pii: djv340. doi: 10.1093/jnci/djv340. Print 2016 Mar.

PMID:
26683220
3.

Donor-derived stem-cells and epithelial mesenchymal transition in squamous cell carcinoma in transplant recipients.

Verneuil L, Leboeuf C, Bousquet G, Brugiere C, Elbouchtaoui M, Plassa LF, Peraldi MN, Lebbé C, Ratajczak P, Janin A.

Oncotarget. 2015 Dec 8;6(39):41497-507. doi: 10.18632/oncotarget.6359.

4.

Reply to 'Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance' by Funck-Brentano et al.

Goldwirt L, Chami I, Feugeas JP, Pages C, Brunet-Possenti F, Allayous C, Baroudjian B, Madelaine I, Sauvageon H, Mourah S, Lebbé C.

Ann Oncol. 2016 Feb;27(2):363-4. doi: 10.1093/annonc/mdv538. Epub 2015 Nov 16. No abstract available.

PMID:
26578723
5.

Dramatic transient improvement of metastatic BRAFV600E-mutated Langerhans cell sarcoma under treatment with dabrafenib.

Mourah S, Lorillon G, Meignin V, Vercellino L, de Margerie-Mellon C, Pages C, Goldwirt L, How-Kit A, Tost J, Lebbe C, Tazi A.

Blood. 2015 Dec 10;126(24):2649-52. doi: 10.1182/blood-2015-06-650036. Epub 2015 Oct 14. No abstract available.

PMID:
26468227
6.

Integrating first-line treatment options into clinical practice: what's new in advanced melanoma?

Dummer R, Schadendorf D, Ascierto PA, Larkin J, Lebbé C, Hauschild A.

Melanoma Res. 2015 Dec;25(6):461-9. doi: 10.1097/CMR.0000000000000200.

PMID:
26426764
7.

BRAF inhibitor rechallenge in patients with advanced BRAF V600-mutant melanoma.

Roux J, Pages C, Malouf D, Basset Seguin N, Madjlessi N, Baccard M, Comte C, Archimbaud A, Battistella M, Viguier M, Mourah S, Bagot M, Lebbe C.

Melanoma Res. 2015 Dec;25(6):559-63. doi: 10.1097/CMR.0000000000000196.

PMID:
26397052
8.

Prognostic Value of 25-hydroxyvitamin D3 Levels at Diagnosis and During Follow-up in Melanoma Patients.

Saiag P, Aegerter P, Vitoux D, Lebbé C, Wolkenstein P, Dupin N, Descamps V, Aractingi S, Funck-Brentano E, Autier P, Dragomir M, Boniol M.

J Natl Cancer Inst. 2015 Sep 15;107(12):djv264. doi: 10.1093/jnci/djv264. Print 2015 Dec.

PMID:
26376687
9.

Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline.

Lebbe C, Becker JC, Grob JJ, Malvehy J, Del Marmol V, Pehamberger H, Peris K, Saiag P, Middleton MR, Bastholt L, Testori A, Stratigos A, Garbe C; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC).

Eur J Cancer. 2015 Nov;51(16):2396-403. doi: 10.1016/j.ejca.2015.06.131. Epub 2015 Aug 6. Review.

PMID:
26257075
10.

Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline.

Stratigos A, Garbe C, Lebbe C, Malvehy J, del Marmol V, Pehamberger H, Peris K, Becker JC, Zalaudek I, Saiag P, Middleton MR, Bastholt L, Testori A, Grob JJ; European Dermatology Forum (EDF); European Association of Dermato-Oncology (EADO); European Organization for Research and Treatment of Cancer (EORTC).

Eur J Cancer. 2015 Sep;51(14):1989-2007. doi: 10.1016/j.ejca.2015.06.110. Epub 2015 Jul 25. Review.

PMID:
26219687
11.

Diagnosis and treatment of dermatofibrosarcoma protuberans. European consensus-based interdisciplinary guideline.

Saiag P, Grob JJ, Lebbe C, Malvehy J, Del Marmol V, Pehamberger H, Peris K, Stratigos A, Middelton M, Basholt L, Testori A, Garbe C.

Eur J Cancer. 2015 Nov;51(17):2604-8. doi: 10.1016/j.ejca.2015.06.108. Epub 2015 Jul 16.

PMID:
26189684
12.

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.

Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JB, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG, Swann S, Legos JJ, Jin F, Mookerjee B, Flaherty K.

Lancet. 2015 Aug 1;386(9992):444-51. doi: 10.1016/S0140-6736(15)60898-4. Epub 2015 May 31.

PMID:
26037941
13.

Paradoxical simultaneous regression and progression of lesions in a phase II study of everolimus in classic Kaposi sarcoma.

Mourah S, Porcher R, Battistella M, Kerob D, Guillot B, Jouary T, Agbalika F, Morinet F, Furlan V, Teisserenc HM, Dupin N, Lebbé C.

Br J Dermatol. 2015 Nov;173(5):1284-7. doi: 10.1111/bjd.13897. Epub 2015 Aug 19. No abstract available.

PMID:
25970141
14.

The ipilimumab lesson in melanoma: achieving long-term survival.

Delyon J, Maio M, Lebbé C.

Semin Oncol. 2015 Jun;42(3):387-401. doi: 10.1053/j.seminoncol.2015.02.005. Epub 2015 Feb 17. Review.

PMID:
25965357
15.

Ultrasound-guided core needle biopsy of superficial lymph nodes: an alternative to fine-needle aspiration cytology for the diagnosis of lymph node metastasis in cutaneous melanoma.

Bohelay G, Battistella M, Pagès C, de Margerie-Mellon C, Basset-Seguin N, Viguier M, Kerob D, Madjlessi N, Baccard M, Archimbaud A, Comte C, Mourah S, Porcher R, Bagot M, Janin A, De Kerviler E, Lebbé C.

Melanoma Res. 2015 Dec;25(6):519-27. doi: 10.1097/CMR.0000000000000161.

PMID:
25933210
16.

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.

Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M, Konto C, Hoos A, de Pril V, Gurunath RK, de Schaetzen G, Suciu S, Testori A.

Lancet Oncol. 2015 May;16(5):522-30. doi: 10.1016/S1470-2045(15)70122-1. Epub 2015 Mar 31. Erratum in: Lancet Oncol. 2015 Jun;16(6):e262.

PMID:
25840693
17.

EMMPRIN/CD147 is a novel coreceptor of VEGFR-2 mediating its activation by VEGF.

Khayati F, Pérez-Cano L, Maouche K, Sadoux A, Boutalbi Z, Podgorniak MP, Maskos U, Setterblad N, Janin A, Calvo F, Lebbé C, Menashi S, Fernandez-Recio J, Mourah S.

Oncotarget. 2015 Apr 30;6(12):9766-80.

18.

EMMPRIN regulates β1 integrin-mediated adhesion through Kindlin-3 in human melanoma cells.

Delyon J, Khayati F, Djaafri I, Podgorniak MP, Sadoux A, Setterblad N, Boutalbi Z, Maouche K, Maskos U, Menashi S, Lebbé C, Mourah S.

Exp Dermatol. 2015 Jun;24(6):443-8. doi: 10.1111/exd.12693. Epub 2015 Apr 16.

PMID:
25807898
19.

Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma.

Schadendorf D, Amonkar MM, Stroyakovskiy D, Levchenko E, Gogas H, de Braud F, Grob JJ, Bondarenko I, Garbe C, Lebbe C, Larkin J, Chiarion-Sileni V, Millward M, Arance A, Mandalà M, Flaherty KT, Nathan P, Ribas A, Robert C, Casey M, DeMarini DJ, Irani JG, Aktan G, Long GV.

Eur J Cancer. 2015 May;51(7):833-40. doi: 10.1016/j.ejca.2015.03.004. Epub 2015 Mar 17.

PMID:
25794603
20.

[Molecular alterations in melanoma and targeted therapies].

Mourah S, Lebbé C.

Bull Cancer. 2014 Dec;101 Suppl 2:S5-S11. doi: 10.1684/bdc.2014.2055. Review. French.

PMID:
25776766
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk